Related Experiment Video

Updated: Dec 31, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.9K

A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma

Swetha Kambhampati1, Derek Galligan2, Chiung-Yu Huang3

  • 1Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA.

Leukemia & Lymphoma
|January 14, 2020
PubMed

Insights

Venetoclax shows promise for relapsed refractory multiple myeloma (RRMM). It demonstrated efficacy, particularly in patients with the t(11;14) genetic marker, suggesting a potential new treatment option.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Venetoclax, a BCL-2 inhibitor, shows preclinical and early clinical promise in relapsed refractory multiple myeloma (RRMM).
  • Clinical application of venetoclax in RRMM requires further investigation.

Purpose of the Study:

  • To evaluate the safety and efficacy of off-label venetoclax use in patients with RRMM.
  • To assess treatment outcomes based on the presence of the t(11;14) chromosomal translocation.

Main Methods:

  • Retrospective analysis of 47 RRMM patients treated with off-label venetoclax at a single center.
  • Analysis of patient demographics, prior therapies, treatment regimens, and clinical outcomes.
  • Subgroup analysis for patients with known t(11;14) translocation.

Main Results:

  • Overall response rate (ORR) was 39%, with 17% achieving very good partial response (VGPR).
  • In the t(11;14) subgroup, ORR was 71%, with 24% achieving VGPR.
  • Median progression-free survival was 2.1 months, and median overall survival was 15.6 months. One treatment-related death occurred.

Conclusions:

  • Venetoclax appears safe and effective in RRMM patients, especially those with t(11;14).
  • Further evaluation in prospective clinical trials is warranted to confirm these findings.
Keywords:
Venetoclaxbortezomibmyelomaresponsetranslocation t(11;14)

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

490

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
182
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
152
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
204
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K